Effect of Pidotimod combined with recombinant human interferon α1b and Ganciclovir in the treatment of children with EB virus associated infectious mononucleosis#br#
ZHANG Hui1 LI Hongyuan2 ZHANG Jianming1▲
1.The Second Department of Pediatrics, Fuyang Women and Children’s Hospital, Anhui Province, Fuyang 236000, China;
2.Department of Child Health Care, Fuyang Women and Children’s Hospital, Anhui Province, Fuyang 236000, China
Abstract：Objective To investigate the effect of Pidotimod combined with recombinant human interferon α1b and Ganciclovir in the treatment of children with Epstein-Barr virus (EBV） associated infectious mononucleosis. Methods A total of 80 children with EBV associated infectious mononucleosis admitted to Department of Pediatrics, Fuyang Women and Children’s Hospital, Anhui Province from January 2018 to March 2021 were selected, and they were divided into observation group and control group by random number table method, with 40 cases in each group. Control group was treated with recombinant human interferon α1b and Ganciclovir, and observation group was treated with Pidotimod on the basis of control group, two groups were treated for ten days. Clinical symptoms improved conditions, CD4+, CD8+, CD4+/CD8+, tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), interleukin-6 (IL-6), creatine kinase (CK), creatine kinase MB (CK-MB), lactate dehydrogenase (LDH), and aspartate aminotransferase (AST) levels were compared, the occurrence of adverse reactions during treatment were recorded. Results The disappearance time of pharyngeal pain, antipyretic time, and relief time of tonsil and lymph node enlargement in observation group were shorter than those in control group, and the differences were statistically significant (P < 0.05). After treatment, CD4+, CD8+, and CD4+/CD8+ in both groups were higher than those before treatment, and observation group was higher than control group, and the differences were statistically significant (P < 0.05). After treatment, the levels of TNF-α, CRP, and IL-6 in two groups were lower than those before treatment, and observation group was lower than control group, and the differences were statistically significant (P < 0.05). After treatment, the levels of CK, CK-MB, LDH, and AST in two groups were lower than those before treatment, and observation group was lower than control group, and the differences were statistically significant (P < 0.05). During the treatment, no obvious adverse reactions occurred in two groups. Conclusion Pidomord combined with recombinant human interferon α1b and Ganciclovir in the treatment of children with EBV associated infectious mononucleosis have obvious effect, it’s worthy of promotion and application.
张辉1 李虹媛2 张建明1▲. 匹多莫德联合重组人干扰素α1b及更昔洛韦治疗EB病毒相关性传染性单核细胞增多症患儿的效果[J]. 中国医药导报, 2022, 19(3): 99-102.
ZHANG Hui1 LI Hongyuan2 ZHANG Jianming1▲. Effect of Pidotimod combined with recombinant human interferon α1b and Ganciclovir in the treatment of children with EB virus associated infectious mononucleosis#br#. 中国医药导报, 2022, 19(3): 99-102.
京公网安备 11010502046598号